Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 84 matching trials from the live ClinicalTrials.gov search.
Terminated Not applicable Interventional Results available

Transnasal Cooling for Migraine

NCT04936061
Conditions
Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
Interventions
CoolStat active device, CoolStat sham device
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • East Lansing, Michigan • Charlotte, North Carolina
Completed Phase 2Phase 3 Interventional Results available

Rizatriptan for Episodic Dizziness in Vestibular Migraine

NCT02447991
Conditions
Vestibular Migraine, Migrainous Vertigo
Interventions
Rizatriptan, Placebo
Drug
Lead sponsor
Robert W. Baloh
Other
Eligibility
18 Years to 65 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Little Rock, Arkansas • Banning, California • Loma Linda, California + 38 more
Conditions
Migraine, Episodic Migraine
Interventions
Galcanezumab, Rimegepant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more
Conditions
Migraine Disorders
Interventions
gammaCore Sapphire active, gammaCore Sapphire Sham
Device
Lead sponsor
ElectroCore INC
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Scottsdale, Arizona • Carlsbad, California • Palo Alto, California + 27 more
Conditions
Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases
Interventions
Not listed
Lead sponsor
Lifegraph Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Detroit, Michigan • West Bloomfield, Michigan
Conditions
Migraine Headaches
Interventions
Sumatriptan 10 mg Nasal Spray, Sumatriptan Placebo Nasal Spray
Drug · Other
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
San Diego, California • Santa Monica, California • Boston, Massachusetts + 6 more
Conditions
Migraine
Interventions
Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more
Conditions
Migraine Disorders
Interventions
ALD403, Placebo
Drug
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more
Conditions
Migraine
Interventions
No intervention: We are testing for the presence of allodynia
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Migraine, With or Without Aura
Interventions
Atogepant, Placebo-matching Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
Conditions
Migraine
Interventions
ALD403, Placebo
Biological · Drug
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 23 more
Completed No phase listed Observational Results available

Prospective ED Headache Cohort Study

NCT00313703
Conditions
Headache
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Episodic Migraine
Interventions
Sham Treatment Location, Verum Treatment Location
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Chronic Migraine or Episodic Migraine
Interventions
Placebo, AMG 301
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
Conditions
Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
Interventions
Mi-Helper
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
178
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Conditions
Migraine Headache
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Encino, California + 34 more
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety of DFN-15

NCT03009019
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Conditions
Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
Interventions
Neurostimulator
Device
Lead sponsor
Salvia BioElectronics
Industry
Eligibility
22 Years to 84 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Newnan, Georgia • Olney, Maryland • Charlotte, North Carolina
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
80
States / cities
Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 72 more
Recruiting Not applicable Interventional

Chiropractic Care for Episodic Migraine

NCT06229834
Conditions
Episodic Migraine
Interventions
Chiropractic Care, Headache Health Education
Procedure · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts